tetradecanoylphorbol acetate
Small moleculeexperimental
12-O-Tetradecanoylphorbol-13-acetate (TPA), also commonly known as tetradecanoylphorbol acetate, tetradecanoyl phorbol acetate, and phorbol 12-myristate 13-acetate (PMA) is a diester of phorbol. It is a potent tumor promoter often employed in biomedical research to activate the signal transduction enzyme protein kinase C (PKC). The effects of TPA on PKC result from its similarity to one of the natural activators of classic PKC isoforms, diacylglycerol. TPA is a small molecule drug. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 1998 (NCT00004058)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
Also known as
- 12-o-tetradecanoylphorbol-13-acetate
- 12-o-tetradecanoylphorbol-13-acetate
- tetradecanoylphorbol acetate
- tetradecanoylphorbol acetate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01009931 | Phase 2 | Mar 1, 2011 | Biosuccess Biotech Co., Ltd., National Cancer Institute (NCI), Rutgers University |
| NCT00004058 | Phase 1 | Dec 1, 1998 | National Cancer Institute (NCI), Rutgers University, University of Medicine and Dentistry of New Jersey |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1998 |
| Rutgers University | Academic/Hospital | 2 | 1 | 2 | 1998 |
| Biosuccess Biotech Co., Ltd. | For profit | 1 | 0 | 1 | 2011 |
| University of Medicine and Dentistry of New Jersey | Academic/Hospital | 1 | 1 | 1 | 1998 |
4 organizations
Page 1 / 1